

HOME | ABOUT | LOGIN | CATEGORIES | SEARCH | CURRENT | ARCHIVES | ANNOUNCEMENTS

Home > Vol 13, No 1 (2025)

USER

Username

Password

Remember me

Login

Global Medical and Health Communication Indexed by:

    

<https://doi.org/10.2460/5441>

GLOBAL MEDICAL & HEALTH COMMUNICATION (GMHC)

Global Medical and Health Communication is a journal that publishes medical and health articles published since 2013. Articles are original research that needs to be disseminated and written in **English**.

In not so long time, **Global Medical and Health Communication** that managed by the **Faculty of Medicine, Universitas Islam Bandung (Unisba)** and published by **UPT Publikasi Ilmiah Unisba** already accredited by the National Journal Accreditation (**Arjuna**) managed by the Directorate General of Higher Education, Research, and Technology, Ministry of Education, Culture, Research, and Technology of the Republic of Indonesia with 2nd Grade (**Sinta 2**) starting from Volume 7 Number 2 of 2019 to Volume 12 Number 2 of 2024. It's also Indexed in the **Directory of Open Access Journals (DOAJ)** on 9th May 2017 and Crossref on 2nd January 2018. With DOAJ and Crossref indexing, this journal can reach international audiences.

This achievement received a positive response from researchers, lecturers, and health observers indicated by the articles submitted, three times the number of articles received initially. The quality of the articles also shows improvement in terms of methodology and writing that is useful for audiences. Research results were best to disseminate as early as possible to good use. Publication of the **Global Medical and Health Communication** every **6 (six) months** in a year will be published every **4 (four) months** starting in 2017.

The news from science and health about challenges and opportunities in Indonesia is still very rare and **Global Medical and Health Communication** hopes to become the best means to support researchers, lecturers, and health practitioners to become the voice of Indonesia, especially in health.

pISSN 2301-9123 | eISSN 2460-5441



ACCREDITATION


Number: 30/E/KPT/2019



48 Scopus[®] citations

AUTHOR GUIDELINES

Editorial

HOME | ABOUT | LOGIN | CATEGORIES | SEARCH | CURRENT | ARCHIVES | ANNOUNCEMENTS

USER

Username

Password

Remember me

Login

Global Medical and Health Communication Indexed by:

       

Global Medical and Health Communication Submission Template

EDITORIAL TEAM

Editor in Chief
Santun Bhdki Rahimah, Department of Pharmacology, Faculty of Medicine, Universitas Islam Bandung, Bandung, Indonesia

Managing Editor
Winni Maharani, Department of Microbiology, Faculty of Medicine, Universitas Islam Bandung, Bandung, Indonesia

External Editorial Board
Badru Hisham Yahaya, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Kepala Batas, Malaysia
Jerico Franciscus Pardoli, School of Public Health and Social Work, Queensland University of Technology, Kelvin Grove, Queensland, Australia
Roy Riller Marzo, Asia Metropolitan University, Johor, Malaysia

Internal Editorial Board
Ike Rahmawaty Alie, Department of Physiology, Faculty of Medicine, Universitas Islam Bandung, Bandung, Indonesia
Indri Budarti, Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Islam Bandung, Bandung, Indonesia
Lisa Adinia Garina, Department of Child Health, Faculty of Medicine, Universitas Islam Bandung, Bandung, Indonesia
Mirasari Putri, Department of Biochemistry, Nutrition, and Biomolecular, Faculty of Medicine, Universitas Islam Bandung, Bandung, Indonesia
Yuktiana Kharisma, Department of Pathology Anatomy, Faculty of Medicine, Universitas Islam Bandung, Bandung, Indonesia

Proofreader
Herry Garna, Department of Child Health, Faculty of Medicine, Universitas Islam Bandung, Bandung, Indonesia

Copyeditor
Yudi Ferliandi, Department of Medical Education, Bioethics, Humaniora and Islamic Insert, Faculty of Medicine, Universitas Islam Bandung, Bandung, Indonesia

Layout Editor
Agus Chalid, Faculty of Medicine, Universitas Islam Bandung, Bandung, Indonesia

Editorial Assistants

ACCREDITATION


Number: 30/E/KPT/2019



48 Scopus[®] citations

AUTHOR GUIDELINES

ONLINE SUBMISSION

FOCUS AND SCOPE

EDITORIAL TEAM

PEER REVIEWERS

PUBLICATION ETHICS

ABSTRACT AND INDEXING

RESEARCH ARTICLE**Serum High-Density Lipoprotein-Cholesterol Concentration as Determinant of Poor Glycemic Control in Type 2 Diabetes Mellitus Patients at a Public Health Center in Jakarta, Indonesia**

Yenny,¹ Patricia Budihartanti Liman,² Joice Viladelphia Kalumpiu,¹ Triasti Khusfiani,¹ Jihan Samira,³ Arleen Devita³

¹Department of Pharmacology and Clinical Pharmacy, Faculty of Medicine, Universitas Trisakti, West Jakarta, Indonesia,

²Department of Nutrition, Faculty of Medicine, Universitas Trisakti, West Jakarta, Indonesia, ³Department of Microbiology, Faculty of Medicine, Universitas Trisakti, West Jakarta, Indonesia

Abstract

The risk factors for glycemic control in type 2 diabetes mellitus (T2DM) are poorly understood. This study assessed the prevalence of poor glycemic control and the predictive factors of poor glycemic control among T2DM outpatients in the community. This 30-day community-based cross-sectional study was conducted among ambulatory T2DM patients in Jakarta from May to June 2023. Data on age, sex, and level of education were collected by questionnaire, whereas data on body mass index, lipid profile, and HbA1c were obtained by measurement. Glycemic control was good if HbA1c <7 % and poor if HbA1c≥7%. The relationships between age, sex, level of education, body mass index, lipid profile, and glycemic control were determined using simple logistic regression. Multivariable logistic regression was used to determine the most influential risk factors of glycemic control. Poor glycemic control was found in 68.4% respondents, and obesity in 57.9% of respondents. After adjustment for age, level of education, and triglyceride concentration, the most influential factor for glycemic control was HDL concentration (aOR=4.43, 95% CI=1.19–16.5, p=0.027). Patients with T2DM with HDL <40 mg/dl had a 4.63 times significantly higher odds of poor glycemic control than those with HDL ≥40 mg/dl. This study found a high prevalence of poor glycemic control in the community setting among individuals with T2DM, with HDL concentration as the most significant predictor. Meanwhile, a triglyceride concentration of ≥150 mg/dl independently provided 58% greater protection against glycemic control (p=0.035), but the effect was not significant after adjustment (p>0.05). The high prevalence of poor glycemic control, dyslipidemia, and obesity in T2DM patients requires routine screening and monitoring accompanied by health education on lifestyle modification for risk factor control, thus minimizing the risk of complications.

Keywords: Indonesia; risk factors; serum high-density lipoprotein-cholesterol; type 2 diabetes; urban population

Introduction

HbA1c levels below 7% to reduce cardiovascular risk, with each 1% increase associated with a 13% rise in Type 2 diabetes mellitus (T2DM) continues to rise globally, risk.^{5,6} Despite its importance, the prevalence of poor with a prevalence of 6,138.6 per 100,000 population in glycemic control remains high across many settings, 2021 and a projected 59.7% increase by 2050.¹ Indonesia including Saudi Arabia (49.1%),⁷ Malaysia (59.2%),⁸ faces a similar trend, ranking fifth worldwide with 19.5 Ethiopia (61.1%),⁹ million T2DM cases in 2021, expected to reach 28.6 Uganda (84.3%),¹⁰ and Egypt (93%).¹¹ million by 2045.^{2,3} Poor glycemic control contributes Multiple studies have explored various predictors of substantially to cardiovascular complications in T2DM, glycemic control, including age,^{9,10,12} sex,^{13,14} as endothelial dysfunction and coronary artery disease education,^{9,15} BMI,^{13,16} and comorbidities, but the are exacerbated by elevated glycated hemoglobin findings remain inconsistent. These inconsistencies (HbA1c).⁴ The American Diabetes Association (ADA) also extend to research on lipid profiles, where their recommends maintaining connection to glycemic control remains far from settled. Some studies report

Copyright @2025 by authors. This is an open access article under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (<https://creativecommons.org/licenses/by-nc-sa/4.0/>).

Received: 23 June 2025; Revised: 22 November 2025; Accepted: 27 November 2025; Published: 19 December 2025

Correspondence: Yenny. Department of Pharmacology and Clinical Pharmacy, Faculty of Medicine, Universitas Trisakti. Jl. Kyai Tapa No. 1, West Jakarta 11440, Special Capital Region of Jakarta, Indonesia. E-mail: yennyfarmako@trisakti.ac.id

significant associations between dyslipidemia and poor glycemic control, particularly involving HDL cholesterol. Haghishatpanah et al.¹⁶ and Wang et al.¹⁷ found that abnormal HDL levels increased the odds of poor glycemic control (1.72- and 2.17-fold, respectively). Abd-Elraouf et al.¹¹ also identified elevated LDL and total cholesterol as predictors of higher HbA1c. In contrast, Awadalla et al.¹⁸ reported no significant differences in HDL, LDL, triglycerides, or total cholesterol between patients with controlled and uncontrolled glycemia.

These inconsistencies underscore that we still have unanswered questions about the role of serum HDL cholesterol in determining glycemic control among people with T2DM. Although several studies suggest HDL abnormalities may contribute to poor glycemic regulation, their findings are not uniform. Moreover, there is limited local evidence from Indonesia, a country with rapidly increasing T2DM prevalence and unique demographic, dietary, and health-system characteristics. Local data are therefore essential to determine whether HDL is an important predictor of glycemic control in Indonesian patients, particularly in the early years following diagnosis, a critical period for preventing long-term complications.¹⁹

This study aimed to measure the prevalence of poor glycemic control among T2DM cases newly diagnosed in the last 5 years and to identify its influencing factors, as measured by glycosylated hemoglobin.

Methods

This analytical, observational, cross-sectional study was conducted on ambulatory T2DM patients at a public health center in Jakarta from May to June 2023. A total of 114 patients with T2DM were collected by consecutive non-random sampling. The inclusion criteria for prospective subjects were: patients with T2DM if meeting one of the following ADA criteria:²⁰ HbA1c $\geq 6.5\%$ or fasting blood glucose ≥ 126 mg/dl (7.0 mmol/l) or 2-hour post prandial blood glucose ≥ 200 mg/dl (11.1 mmol/l) during the oral glucose tolerance test (OGTT), or random plasma glucose ≥ 200 mg/dl (11.1 mmol/l); capable of good verbal communication, and agreeing to become study subjects by giving written informed consent. The exclusion criteria were ever receiving or currently

receiving insulin therapy and hypolipidemic drugs, having cardiovascular disease, or abnormal liver or renal function.

The sample size was computed using (1) the formula for an infinite (unknown) population and (2) the formula for a finite (known) population:

description: n_0 : required optimal sample size, Z_α : 1.96, p : prevalence of poor glycemic control in diabetes mellitus = 59.2% = 0.592,⁸ q : $(1-p)$ = 0.408, determined degree of confidence or accuracy of measurement = 0.05, resulting in n_0 = 371.

The sample size was calculated using the Dobson formula for a cross-sectional study and adjusted for the finite population. Based on a 59.2% prevalence of poor glycemic control,⁸ 95% confidence, and 5% margin of error, the initial sample size was 371. Given that the total number of persons with T2DM at the study site was 228, the finite population correction yielded a final sample size of 114.

The data collected in this study comprised the characteristics of age, sex, and level of education, followed by the determination of body mass index and drawing of venous blood for the determination of blood lipid concentrations (TC, TG, HDL cholesterol, LDL cholesterol) and of HbA1c for evaluation of the glycemic control of the respondents. Age was categorized into elderly (≥ 60 years) and non-elderly (< 60 years), sex into male and female, and level of education into low (no formal schooling–junior high school) and high (senior high school–tertiary education). Height and weight were determined by means of a portable microtoise and Sage portable scales in accordance with the WHO procedures.²¹

Subjects were asked to remove their footwear, hat, hair accessories, or any high hairdos, take off belts, and empty their pockets to remove cell phones, wallets, or coins. In measuring height, the subject was asked to stand with the feet together, heels against the wall, knees straight, and eyes on the same level as the ears. The measuring arm was gently slid down onto the head, and the subject was asked to breathe in, with the results

recorded to an accuracy of 0.1 cm. To determine body weight, the portable scale was placed on a firm, flat surface. The scale was then switched on until the data were presented as the number of digits appeared. The subject was then asked to step onto the scale, face forward, arms at the sides, and stand still. The weight was recorded to an accuracy of 0.1 cm. socio-demographic characteristics (age, sex, Body mass index (BMI) was calculated by dividing the weight in kg by the square of the height in meters, and was glycemic control were evaluated using simple logistic regression; variables with p -values ≤ 0.25 were then classified into non-obese ($BMI < 25 \text{ kg/m}^2$) and obese ($BMI \geq 25 \text{ kg/m}^2$) in accordance with the WHO Asia-Pacific tested in multivariate logistic regression to identify BMI categories.²²

After an overnight fast of 10 to 12 hours, a total of 10 ml control for confounding factors. A two-tailed $p < 0.05$ of venous blood was collected in vacutainers with and was considered statistically significant. Statistical without EDTA. For HbA1c determination, EDTA-treated analyses were performed using SPSS version 25.0 blood was directly examined. In contrast, for the (IBM Corp., NY, USA). Our study received ethical determination of blood lipid levels (TC, TG, HDL cholesterol, and LDL cholesterol), venous blood samples Faculty of Medicine, Universitas Trisakti, under without EDTA were centrifuged at 2000 RPM for 10 minutes. The obtained serum was frozen at -70°C before

use for laboratory examinations, performed **Results** simultaneously on samples from all subjects and assessed

by enzymatic colorimetry using the Roche Cobas c111 The median age of respondents was 56 (35– 80) instrument (Germany). Blood lipids were categorized by years; the majority were females (72.8%), with the means of the criteria of the Third Report of the Expert most frequent level of education being senior high Panel on Detection, Evaluation, and Treatment of High school (33.3%). The majority of the subjects (77.2%) Blood Cholesterol in Adults (Adult Treatment Panel III, had malnutrition, with 1.8%

or ATP III).²² Total cholesterol was categorized into <200 undernutrition, 17.5% overweight, and 57.9% obese. and $\geq 200 \text{ mg/dl}$, triglycerides into <150 mg and $\geq 150 \text{ mg/dl}$. Dyslipidemia was also apparent in the majority of the mg/ dl, HDL cholesterol into ≥ 40 and <40 mg/dl, and respondents, with high levels of cholesterol, LDL, and LDL cholesterol into <100 and $\geq 100 \text{ mg/dl}$. Glycemic triglycerides. However, the majority of respondents control was based on hemoglobin A1c (HbA1c) (73.7%) had HDL concentrations $\geq 40 \text{ mg/dl}$. The concentration and categorized in line with the ADA prevalence of respondents with poor glycemic control criteria into good (HbA1c <7%) and poor (HbA1c $\geq 7\%$).⁵ was 78 (68.4%). Still, there was no significant Data cleaning was performed before data analysis, using difference in age, BMI, or blood lipids between those consistency, range, and logical checks. We recheck the with poor and good glycemic control (Table 1).

laboratory value involved by verifying the original Four variables met the requirements for a laboratory reports, confirming unit consistency, and multivariable logistic regression ($p < 0.25$): age screening for any data-entry errors. Values represent ($p = 0.091$), level of education ($p = 0.210$), triglyceride actual biological variation and not measurement artifacts; concentration ($p = 0.035$), and high-density we did not apply additional outlier- handling or lipoprotein concentration ($p = 0.007$, Table 2).

transformation procedures.

The results of multivariate analysis, after adjustment We used the Kolmogorov-Smirnov test to determine the for age, level of education, and triglyceride normality of the distribution of all numerical variables. concentration, showed that the most influential

Normally distributed numerical data were presented factor of glycemic control in patients with T2DM as mean \pm SD,

was HDL cholesterol concentration. Patients with T2DM who had an HDL concentration of <40 mg/dl had 4.43 times higher odds of poor glycemic control compared

Table 1 Subject Characteristics

Glycemic Control Variables	All Subjects	Good (n=36)	Poor (n=78)	p-value
Age (years) ^a	56 (35–80)	60 (39–79)	53.50 (35–80)	0.441 ^{\$}
Body mass index (kg/m ²) ^b	26.29±4.57	26.8±5.03	26.04±4.36	0.395 [#]
Blood lipids (mg/dl)				
Total cholesterol ^b	209.47±44.09	201.97±33.17	212.94±48.10	0.161 [*]
Triglycerides ^a	154 (52–1593)	125.5 (61–322)	168.5 (52–1593)	0.060 ^{\$}
HDL cholesterol ^b	45.86±9.65	47 (30–83)	43.5 (24–78)	0.064 ^{\$}
LDL cholesterol ^a	135 (43–324)	135.36±29.5	144.41±43.37	0.259 [#]
Glycemic control, n (%)				
Good	36 (31.6)			
Poor	78 (68.4)			

Note: values presented as amedian (min–max), bmean±SD. Data analysis: *independent t-test, ^{\$}Mann-Whitney test. Classification of categorical data: glycemic control categorized into good (HbA1c <7%) and poor (HbA1c ≥7%)⁵

Table 2 Relationship of Several Risk Factors with Glycemic Control in Study Subjects

Variables	Glycemic Control ^a		OR	95% CI	p-value ^b
	Good n=36 (%)	Poor n=78 (%)			
Age (years)					
Non-elderly	17 (25.4)	50 (74.6)	1	0.90–4.45	0.091 ^{\$}
Elderly	19 (40.4)	28 (59.6)	1.99		
Sex					
Female	27 (32.5)	56 (62.5)	1	0.34–2.10	0.721
Male	9 (29.0)	22 (71.0)	0.85		
Level of education					
Low	23 (36.5)	40 (63.5)	1	0.26–1.34	0.210
High	13 (25.5)	38 (74.5)	0.59		
Body mass index (kg/m ²)					
Non-obese	13 (27.1)	35 (72.9)	1	0.64–3.25	0.386
Obese	23 (34.8)	43 (65.2)	1.44		
Blood lipids (mg/dl)					
Cholesterol concentration					
<200	17 (32.7)	35 (67.3)	0.91	0.41–2.01	0.815
≥200	19 (30.6)	43 (69.4)	1		
Triglyceride concentration					
<150	22 (41.5)	31 (58.5)	0.42	0.19–0.94	0.035 ^{\$}
≥150	14 (23.0)	47 (77.0)	1		
HDL concentration					
<40	3 (10.0)	27 (90.0)	5.82	1.63–20.75	0.007 ^{\$}
≥40	33 (39.3)	51 (60.7)	1		
LDL concentration					
<100	3 (30.0)	7 (70.0)	1.08	0.26–4.46	0.910
≥100	33 (31.7)	71 (68.3)	1		

Note: ^aclassification of categorical data: level of education categorized into low (no formal schooling–junior high school) and high (senior high school–tertiary education); age categorized into elderly (≥60 years) and non-elderly (<60 years); BMI categorized into obese (BMI ≥25 mg/kg²) and non-obese (BMI <25 kg/m²); glycemic control categorized into good (HbA1c <7%) and poor (HbA1c ≥7%); OR: odds ratio; CI: confidence interval; ^bstatistical analysis with simple logistic regression test; ^{\$}p-value <0.25 meets requirements for performing analysis with the multivariable logistic regression test

Table 3 Results of Multivariable Logistic Regression Analysis

Variables	aOR	95% CI	p-value ^a
Age (years)			
Non-elderly	1	0.52–3.12	0.594
Elderly	1.28		
Level of education Low			
High	1	0.28–1.77	0.458
Triglyceride concentration (mg/dl)			
<150	0.49	0.20–1.16	0.105
≥150	1		
Glycemic control, n (%)			
<40	4.43	1.19–16.5	0.027*
≥40	1		

Note: aOR: adjusted odds ratio, CI: confidence interval, ^astatistical analysis with multiple logistic regression test, *statistical significance at p-value <0.05

to those with an HDL concentration of ≥40 mg/dl (Table 3).

Discussion

In our study, poor glycemic control was found in around actively take promotive and preventive steps by two-third of the patients or 68.4%, which is higher than in instituting T2DM educational programs, T2DM some developing countries, such as Saudi Arabia (49.1%),⁷ screening, increasing primary health service capacity and Malaysia (59.2%),⁸ but lower than in others, such as and capability, such as strengthening the role of Uganda (84.3%)¹⁰ and Egypt (93%).¹¹ The cause of the health cadres, standardization of health services, and different prevalences of poor glycemic control in T2DM home visits, where these services agree with the may be controlled by various factors, such as socio- Indonesian MoH policy, namely the transformation of demographic characteristics, life style, lack of regular primary health care.²⁵

follow up,¹⁹ lack of political will to encourage the Our study showed that age was not a risk factor for poor communities to improve health issues, and lack of glycemic control in T2DM ($p>0.05$). The survey by knowledge of T2DM patients about glycemic control.²³ Tegegne et al.⁹ showed that older age had 2.12 times The varying prevalence of glycemic control may also be the odds of poor glycemic control (aOR=2.12, 95% caused by the different tests used to measure this variable. CI=1.27–2.97). Patrick et al.¹⁰

Moreover, the differing HbA1c cut-off points used to showed that age of the patients was identified to be measure blood glucose concentration may also result in an independent risk factor, where middle age and old the varying prevalences of poor glycemic control. For age had 4.48 and 4.28 times higher odds, respectively, example, some use HbA1c ≥7% as a cut-off point, while for poor glycemic control than did younger age others use HbA1c >7%.²⁴

(aOR=4.48, 95%CI=1.56–14.50, $p=0.009$ and

Based on our study results, most T2DM patients were aOR=4.28, 95%CI= 1.18–15.58, unable to achieve good glycemic control. This finding $p=0.03$, respectively). Different results were shown by should motivate the government and related stakeholders Shamshirgaran et al.¹² suggesting that middle age to more actively find solutions for this problem. Knowledge (50–59 years) and old age groups (60 years of age of the predisposing factors of poor glycemic control can be and older) had 0.48 and 0.44 times lower odds, effectively applied to control T2DM and prevent its respectively, to having poor glycemic control long-term complications. In this

compared to age under 50 years (aOR=0.49, 95% CI=0.28–0.86 and aOR=0.44, 95% CI=0.24–0.80, respectively). Our study

results differ from those of the studies of Tegegne et al.,⁹ Almalki et al.,⁷ and Patrick et al.,¹⁰ who showed that older age was more vulnerable to poor glycemic control than was younger age, and the study of Shamshirgaran et al.¹² showing that older age had a lower risk of poor glycemic control.

The differences between our study and other studies may have been caused by differences in respondent characteristics, with the median age of 56 (35–80) years showing a lower percentage in the elderly age group (41.3%) than in the non-elderly age group (see Table 1). Lifestyle factors (dietary patterns, physical activity, etc.) may also contribute to individual variation and influence glycemic control. Additionally, the consensus is that aging is often associated with poorer glycemic control in people with diabetes due to physiological changes related to age. In contrast, with advancing age, some persons progressively lose the ability to regulate glucose levels as they did when they were younger, making it difficult for them to maintain stable blood sugar levels.²⁶ However, it has been known that the aging process is not identical between individuals and that other factors may affect glycemic control, such as having diabetes for a longer duration, having comorbidities, and poor adherence to diabetes management,^{9,13} which are significantly associated with higher odds of poor glycemic control.

Our study found that educational level was not a risk factor for poor glycemic control in T2DM. The results of the present study agree with those of Athar et al.,¹⁵ who showed that the level of education is not associated with glycemic control. However, differing results were reported by Bereda et al.,¹⁴ Tegegne et al.,⁹ and Traore et al.,²⁷ indicating that education is negatively associated with glycemic control. This may have resulted from different cutoff points for educational levels, comparing the uneducated with the educated, or comparing the educated with the ignorant. In contrast, in our study, we compared lower education (up to junior high school) with higher education (at least senior high school). The cutoff for glycemic control in our study was A1c level, whereas Bereda et al.¹⁴ used fasting glucose >130 mg/dl.

People with a low level of health literacy have poorer health outcomes, such as a higher risk of complications, hospitalization, higher

treatment costs, and higher mortality risk.^{28,29} The influence of health literacy on glycemic control was shown by the study of Butayeva et al.²⁸ Health literacy depends on several factors, such as individual competence, environmental factors, resources, and community context.³⁰ Therefore the authorities should not rely solely on routine formal education, but should also improve community health literacy. In T2DM, better health literacy is associated with better self-management of diabetes-related skills, better understanding of disease-related knowledge, better treatment adherence, and higher glycemic control.^{28,31}

After controlling for other variables using multivariate analysis, our study showed that low HDL concentrations are risk factors for glycemic control in patients with T2DM (see Table 3). Our results agree with those of Wang et al.¹⁷ and Haghishatpanah et al.,¹⁶ showing that HDL concentrations were significantly associated with poor glycemic control. Abd-Elraouf et al.¹¹ reported that increased LDL and TC concentrations were significant predictors of increased HbA1c. Artha et al.³² found that the LDL cholesterol-to-HDL cholesterol ratio is the most influential risk factor for poor glycemic control. Different results were reported by Awadalla et al.,¹⁸ who found no significant differences in TG, TC, LDL, and HDL between the glycemic control group and the uncontrolled group. There are noteworthy inconsistencies between studies. The differences in the study population may lead to contradictory results. These findings reveal that glycemic control prevalence can vary even within the same country, depending on the study region. Overall, it can be hypothesized that inadequate glycemic control is associated with dyslipidemia components in T2DM. These inconsistent results may be partly due to the relative stability of HbA1c over time,¹⁷ while blood lipids are dynamically changing.³³ In addition, studies on the relationship between HbA1c and blood lipids at different time points over a period of time may present different results.¹⁷ Because of the association between glycemic control and blood lipids, it is necessary to take both variables into account to prevent T2DM-associated micro- and macrovascular complications. In T2DM, the high prevalence of metabolic dyslipidemia (elevated triglycerides) and low HDL cholesterol levels may be due to increased free fatty acid flux secondary

to insulin resistance.³⁴

The Action for Health in Diabetes (AHEAD) study on glycemic and hypolipidemic medications, but also for 4,199 overweight/obese adults with T2DM but free of improving weight management, including support for CVD shows that participants with metabolic dyslipidemia lifestyle modification, with adjunctive had a 1.30 higher risk of the composite CVD outcome and pharmacotherapy to reduce the risk of cardiovascular a 1.48 higher risk of coronary artery disease events.³⁵ disease.

Increasing HDL cholesterol in patients with atherogenic metabolic dyslipidemia may help reduce CVD risk associated with high T2DM prevalence, because each 1-terpadu), remains the MoH's strategy as a mg/dl increase in HDL cholesterol results in a 2–3% community-based health initiative and actively lower CVD risk.³⁶ HDL has antidiabetic effects by inhibiting ER stress-induced beta cell apoptosis³⁷ and by non-communicable diseases, as exemplified by T2DM improving insulin sensitivity.³⁸ In T2DM, HDL maintains blood glucose testing.⁴² Therefore, as a rule, the blood glucose concentrations by also removing excess individuals in question compensate for their poor glucose from the circulation. HDL is also cardioprotective general education by more focused attendance at through the mechanism of reverse cholesterol transport, clinical education sessions on their illness. Attention which carries cholesterol and macrophages from the body^{39,40} and protects against ischemia-induced damage, particularly in the heart, through mediation of tissue glucose for energy production.³⁸

Increasing HDL cholesterol in patients with atherogenic metabolic dyslipidemia may help reduce CVD risk, as of diabetes knowledge could be instituted to raise each 1-mg/dL increase in HDL is associated with a 2–3% lower risk of CVD.³⁶ HDL also contributes to glucose glycemic control.⁴³

regulation and insulin sensitivity, providing metabolic benefits relevant to T2DM.^{37,38} Its cardioprotective effects, including its role in reverse cholesterol transport, further intake, physical activity, comorbidities, and support its role in reducing atherosclerotic burden.^{39,40} These established functions offer biological plausibility and mechanistic details have been condensed to maintain fat and processed foods, which was proven to increase focus on the study's findings.

Apart from the inconsistencies in blood lipid or obese adults.⁴⁴ There were also instrument-related parameters related to risk factors for poor glycemic control in T2DM patients, the American College of Cardiology/American Heart Association has classified exchange chromatography, electrophoresis, T2DM patients with a higher atherosclerotic CVD risk immunoassays, and affinity chromatography, each and has suggested lower intakes of low-density lipoprotein cholesterol.⁴¹ The known controllable content of blood samples depends on cardiovascular risk factors in T2DM include the high lifespan and globin chain properties, not exclusively prevalence of poor glycemic control, the prominence of on blood glucose levels.⁴⁵

high LDL-low HDL dyslipidemia, and the presence of Other limitation of our study, as it is well known, the obesity in most respondents. Strategies are needed cross-sectional study design does not allow causal inference, so a prospective study is required. The width of the 95% CI for the TG value in our study. It is hoped that future studies will use this study's data as a basis for increasing the number of study samples.

We used

consecutive sampling in this study because it was the most practical way to recruit all eligible participants during the study period and to ensure that no cases were intentionally skipped. However, as a non-probability sampling method, consecutive sampling may introduce selection bias, as the sample depends on who presents during the recruitment period. We acknowledge this limitation and have applied consistent eligibility criteria across the entire study period to help reduce potential bias. In this study, oral antihyperglycemic use was recorded, but the small number of users precluded meaningful analysis; therefore, these medications were not included in the main results. Subsequent studies can look into the cause of this phenomenon. Further studies that account for the above-mentioned confounding factors should be conducted to reduce bias. The other factors that should be considered in future studies are low adherence to diabetes management, low family support for diabetes mellitus management, presence of abdominal obesity, and presence of a history of hospitalization, which might be associated with prolonged poor control of T2DM.²⁷

Conclusions

HDL concentrations are potential markers for predicting glycemic control in patients with T2DM. Routine HDL examinations and maintenance of HDL at high concentrations may minimize the risk of complications in T2DM subjects through adjunctive pharmacotherapy, particularly in the population of the present study.

Conflict of Interest

The authors have no conflicts of interest to declare.

Acknowledgment

The researchers would like to thank the subjects of this study for their cooperation.

References

1. GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet*. 2023;402(10397):203–34.
2. Wahidin M, Achadi A, Besral B, Kosen S, Nadjib M, Nurwahyuni A, et al. Projection of diabetes morbidity and mortality till 2045 in Indonesia based on risk factors and NCD prevention and control programs. *Sci Rep*. 2024;14(1):5424.
3. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes Res Clin Pract*. 2022;183:109119.
4. Chen S, Shen Y, Liu YH, Dai Y, Wu ZM, Wang XQ, et al. Impact of glycemic control on the association of endothelial dysfunction and coronary artery disease in patients with type 2 diabetes mellitus. *Cardiovasc Diabetol*. 2021;20(1):64.
5. American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes—2020. *Diabetes Care*. 2020; 43(Suppl 1):S66–76.
6. Chen J, Yin D, Dou K. Intensified glycemic control by HbA1c for patients with coronary heart disease and type 2 diabetes: a review of findings and conclusions. *Cardiovasc Diabetol*. 2023;22(1):146.
7. Almalki ZS, Ahmed NJ, Alahmari AK, Alshehri AM, Alyahya SA, Alqahtani A, et al. Identifying the risk factors and the prevalence of poor glycemic control among diabetic outpatients in a rural region in Saudi Arabia. *J Pharm Res Int*. 2021;33(24A):15–23.
8. Amsah N, Md Isa Z, Kassim Z. Poor glycaemic control and its associated factors among type 2 diabetes mellitus patients in southern part of peninsular Malaysia: a registry-based study. *Open Access Mace J Med Sci*. 2022;10(E):422–7.
9. Tegegne KD, Gebeyehu NA, Yirdaw LT, Yitayew YA, Kassaw MW. Determinants of poor glycemic control among type 2 diabetes in Ethiopia: a systematic review and meta-analysis. *Front Public Health*. 2024;12:1256024.
10. Patrick NB, Yadesa TM, Muhindo R, Lutoti S. Poor glycemic control and the contributing factors among type 2 diabetes mellitus patients attending outpatient diabetes clinic

at Mbarara Regional Referral Hospital, Uganda. *Diabetes Metab Syndr Obes.* 2021; 14:3123–30.

11. Abd-Elraouf MSED. Factors affecting glycemic control in type II diabetic patients. *Egypt J Hosp Med.* 2020;81(2):1457–61.
12. Shamshirgaran SM, Mamaghanian A, Aliasgarzadeh A, Aminisani N, Iranparvar Alamdari M, Ataie J. Age differences in diabetes-related complications and glycemic control. *BMC Endocr Disord.* 2017;17(1):25.
13. Demoz GT, Gebremariam A, Yifter H, Alebachew M, Nirayo YL, Gebreslassie G, et al. Predictors of poor glycemic control among patients with type 2 diabetes on follow-up care at a tertiary healthcare setting in Ethiopia. *BMC Res Notes.* 2019;12(1):207.
14. Bereda G, Bereda G. The incidence and predictors of poor glycemic control among adults with type 2 diabetes mellitus in ambulatory clinic of Mettu Karl Referral Hospital, South Western, Ethiopia: a prospective cross sectional study. *Int Arch Endocrinol Clin Res.* 2021;7(1):024.
15. Athar MH, Nisar S, Zubair UB, Mumtaz H. Impact of general education status on glycemic control in patients of diabetes mellitus. *Pak Armed Forces Med J.* 2020; 70(Suppl 1):S26–30.
16. Haghishatpanah M, Nejad ASM, Haghishatpanah M, Thunga G, Mallayasamy S. Factors that correlate with poor glycemic control in type 2 diabetes mellitus patients with complications. *Osong Public Health Res Perspect.* 2018;9(4):167–74.
17. Wang S, Ji X, Zhang Z, Xue F. Relationship between lipid profiles and glycemic control among patients with type 2 diabetes in Qingdao, China. *Int J Environ Res Public Health.* 2020;17(15):5317.
18. Awadalla H, Noor SK, Elmadhoun WM, Bushara SO, Almobarak AO, Sulaiman AA, et al. Comparison of serum lipid profile in type 2 diabetes with and without adequate diabetes control in Sudanese population in north of Sudan. *Diabetes Metab Syndr.* 2018;12(6):961–4.
19. Yahaya JJ, Doya IF, Morgan ED, Ngaiza AI, Bintabara D. Poor glycemic control and associated factors among patients with type 2 diabetes mellitus: a cross-sectional study. *Sci Rep.* 2023;13(1):9673.
20. American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: standards of care in diabetes—2024. *Diabetes Care.* 2023;47(Suppl 1):S20–42.
21. World Health Organization. The WHO STEPwise approach to noncommunicable disease risk factor surveillance [Internet]. Genva: World Health Organization; 2017 [cited 2025 Aug 23]. Available from: <https://www.who.int/docs/default-source/ncds/ncd-surveillance/steps/steps-manual.pdf>.
22. World Health Organization Western Pasific Region, International Association for the Study of Obesity, International Obesity Task Force. The Asia-Pacific perspective: redefining obesity and its treatment. Sydney: Health Communications Australia Pty Ltd; 2000.
23. Fina Lubaki JP, Omole OB, Francis JM. Glycaemic control among type 2 diabetes patients in sub-Saharan Africa from 2012 to 2022: a systematic review and meta-analysis. *Diabetol Metab Syndr.* 2022;14(1):134.
24. Bin Rakhis SA Sr, AlDuwayhis NM, Aleid N, AlBarak AN, Aloraini AA. Glycemic control for type 2 diabetes mellitus patients: a systematic review. *Cureus.* 2022;14(6):e26180.
25. Kementerian Kesehatan Republik Indonesia. Transformasi kesehatan Indonesia [Internet]. Jakarta: Kementerian Kesehatan Republik Indonesia; 2025 [cited 2025 2 March]. Available from: <https://kemkes.go.id/id/layanan/transformasi-kesehatan-indonesia>.
26. Chia CW, Egan JM, Ferrucci L. Age-Related Changes in Glucose Metabolism, Hyperglycemia, and Cardiovascular Risk. *Circulation research.* 2018;123(7):886–904.
27. Traore S, Guira O, Zoungrana L, Sagna Y, Bognounou R, Paré B, et al. Factors associated with prolonged poor glycemic control in type 2 diabetes mellitus (T2DM) patients followed in the Department of Internal Medicine at the Yalgado Ouedraogo Teaching Hospital, Ouagadougou (Burkina Faso). *Open J Intern Med.* 2021;11:1–26.
28. Butayeva J, Ratan ZA, Downie S, Hosseinzadeh H. The impact of health literacy interventions on glycemic control and self-management outcomes among type

2 diabetes mellitus: a systematic review. *J Diabetes*. 2023;15(9):724–35.

29. Ong-Artborirak P, Seangpraw K, Boonyathee S, Auttama N, Winaiprasert P. Health literacy, self-efficacy, self-care behaviors, and glycemic control among older adults with type 2 diabetes mellitus: a cross-sectional study in Thai communities. *BMC Geriatr*. 2023;23(1):297.

30. Sørensen K, Levin-Zamir D, Duong TV, Okan O, Brasil VV, Nutbeam D. Building health literacy system capacity: a framework for health literate systems. *Health Promot Int*. 2021;36(Suppl 1):i13–23.

31. Kim S, Song Y, Park J, Utz S. Patients' experiences of diabetes self-management education according to health-literacy levels. *Clin Nurs Res*. 2020;29(5):285–92.

32. Artha IMJR, Bhargah A, Dharmawan NK, Pande UW, Triyana KA, Mahariski PA, et al. High level of individual lipid profile and lipid ratio as a predictive marker of poor glycemic control in type-2 diabetes mellitus. *Vasc Health Risk Manag*. 2019;15:149–57.

33. B O'Donnell V. Lipidomics moves to center stage of biomedicine. *Function (Oxf)*. 2023; 4(1):zqac071.

34. C Thambiah S, Lai LC. Diabetic dyslipidaemia. *Pract Lab Med*. 2021;26:e00248.

35. Kaze AD, Santhanam P, Musani SK, Ahima R, Echouffo-Tcheugui JB. Metabolic dyslipidemia and cardiovascular outcomes in type 2 diabetes mellitus: findings from the Look AHEAD study. *J Am Heart Assoc*. 2021;10(7):e016947.

36. Ginsberg HN, MacCallum PR. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. *J Cardiometab Syndr*. 2009;4(2):113–9.

37. Lui DTW, Tan KCB. High-density lipoprotein in diabetes: structural and functional relevance. *J Diabetes Investig*. 2024;15(7):805–16.

38. Siebel AL, Heywood SE, Kingwell BA. HDL and glucose metabolism: current evidence and therapeutic potential. *Front Pharmacol*. 2015;6:258.

39. Primer KR, Psaltis PJ, Tan JTM, Bursill CA. The role of high-density lipoproteins in endothelial cell metabolism and diabetes-impaired angiogenesis. *Int J Mol Sci*. 2020; 21(10):3633.

40. Kalumpiu J, Herwana E, Yenny Y, Kurniasari K. Blood pressure, total cholesterol, and triglycerides associated with cardiovascular risk score in low 25-hydroxy vitamin d level among online motorcycle drivers, Jakarta, Indonesia. *GMHC*. 2024;12(1):46–53.

41. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NL A/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2019;73(24):e285–350.

42. Kementerian Kesehatan Republik Indonesia. Direktorat Jendral Pencegahan dan Pengendalian Penyakit. Buku pintar kader posbindu. Jakarta: Kementerian Kesehatan Republik Indonesia; 2019.

43. Elnaggar A, Ta Park V, Lee SJ, Bender M, Siegmund LA, Park LG. Patients' use of social media for diabetes self-care: systematic review. *J Med Internet Res*. 2020;22(4):e14209.

44. Liman PB, Anastasya KS, Salma NM, Yenny Y, Faradilla MA. Research trends in advanced glycation end products and obesity: bibliometric analysis. *Nutrients*. 2022;14(24):5255.

45. Chen Z, Shao L, Jiang M, Ba X, Ma B, Zhou T. Interpretation of HbA1c lies at the intersection of analytical methodology, clinical biochemistry and hematology (review). *Exp Ther Med*. 2022;24(6):707.

Serum High-Density Lipoprotein-Cholesterol Concentration as Determinant of Poor Glycemic Control in Type 2 Diabetes Mellitus Patients at a Public Health Center in Jakarta, Indonesia

By Yenny Yenny

RESEARCH ARTICLE

Serum High-Density Lipoprotein-Cholesterol Concentration as Determinant of Poor Glycemic Control in Type 2 Diabetes Mellitus Patients at a Public Health Center in Jakarta, Indonesia

Yenny,¹ Patricia Budihartanti Liman,² Joice Viladelphia Kalumpiu,¹ Triasti Khusfiani,¹ Jihan Samira,³ Arleen Devita³

¹Department of Pharmacology and Clinical Pharmacy, Faculty of Medicine, Universitas Trisakti, West Jakarta, Indonesia, ²Department of Nutrition, Faculty of Medicine, Universitas Trisakti, West Jakarta, Indonesia,

³Department of Microbiology, Faculty of Medicine, Universitas Trisakti, West Jakarta, Indonesia

Abstract

The risk factors for glycemic control in type 2 diabetes mellitus (T2DM) are poorly understood. This study assessed the prevalence of poor glycemic control and the predictive factors of poor glycemic control among T2DM outpatients in the community. This 30-day community-based cross-sectional study was conducted among ambulatory T2DM patients in Jakarta from May to June 2023. Data on age, sex, and level of education were collected by questionnaire, whereas data on body mass index, lipid profile, and HbA1c were obtained by measurement. Glycemic control was good if $\text{HbA1c} < 7\%$ and poor if $\text{HbA1c} \geq 7\%$. The relationships between age, sex, level of education, body mass index, lipid profile, and glycemic control were determined using simple logistic regression. Multivariable logistic regression was used to determine the most influential risk factors of glycemic control. Poor glycemic control was found in 68.4% respondents, and obesity in 57.9% of respondents. After adjustment for age, level of education, and triglyceride concentration, the most influential factor for glycemic control was HDL concentration ($aOR=4.43$, 95% $CI=1.19$ – 16.5 , $p=0.027$). Patients with T2DM with $\text{HDL} < 40 \text{ mg/dl}$ had a 4.63 times significantly higher odds of poor glycemic control than those with $\text{HDL} \geq 40 \text{ mg/dl}$. This study found a high prevalence of poor glycemic control in the community setting among individuals with T2DM, with HDL concentration as the most significant predictor. Meanwhile, a triglyceride concentration of $\geq 150 \text{ mg/dl}$ independently provided 58% greater protection against glycemic control ($p=0.035$), but the effect was not significant after adjustment ($p>0.05$). The high prevalence of poor glycemic control, dyslipidemia, and obesity in T2DM patients requires routine screening and monitoring accompanied by health education on lifestyle modification for risk factor control, thus minimizing the risk of complications.

Keywords: Indonesia; risk factors; serum high-density lipoprotein-cholesterol; type 2 diabetes; urban population

Introduction

Type 2 diabetes mellitus (T2DM) continues to rise globally, with a prevalence of 6,138.6 per 100,000 population in 2021 and a projected 59.7% increase by 2050.¹ Indonesia faces a similar trend, ranking fifth worldwide with 19.5 million T2DM cases in 2021, expected to reach 28.6 million by 2045.^{2,3} Poor glycemic control contributes substantially to cardiovascular complications in T2DM, as endothelial dysfunction and coronary artery disease are exacerbated by elevated glycated hemoglobin (HbA1c).⁴ The American Diabetes Association (ADA) recommends maintaining

HbA1c levels below 7% to reduce cardiovascular risk, with each 1% increase associated with a 13% rise in risk.^{5,6} Despite its importance, the prevalence of poor glycemic control remains high across many settings, including Saudi Arabia (49.1%),⁷ Malaysia (59.2%),⁸ Ethiopia (61.1%),⁹ Uganda (84.3%),¹⁰ and Egypt (93%).¹¹

Multiple studies have explored various predictors of glycemic control, including age,^{9,10,12} sex,^{13,14} education,^{9,15} BMI,^{13,16} and comorbidities, but the findings remain inconsistent. These inconsistencies also extend to research on lipid profiles, where their connection to glycemic control remains far from settled. Some studies report

Copyright @2025 by authors. This is an open access article under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (<https://creativecommons.org/licenses/by-nc-sa/4.0/>).

Received: 23 June 2025; Revised: 22 November 2025; Accepted: 27 November 2025; Published: 19 December 2025

Correspondence: Yenny, Department of Pharmacology and Clinical Pharmacy, Faculty of Medicine, Universitas Trisakti, Jl. Kyai Tapa No. 1, West Jakarta 11440, Special Capital Region of Jakarta, Indonesia. E-mail: yennyfarmako@trisakti.ac.id

significant associations between dyslipidemia and poor glycemic control, particularly involving HDL cholesterol. Haghishatpanah et al.¹⁶ and Wang et al.¹⁷ found that abnormal HDL levels increased the odds of poor glycemic control (1.72- and 2.17-fold, respectively). Abd-Elraouf et al.¹¹ also identified elevated LDL and total cholesterol as predictors of higher HbA1c. In contrast, Awadalla et al.¹⁸ reported no significant differences in HDL, LDL, triglycerides, or total cholesterol between patients with controlled and uncontrolled glycemia.

These inconsistencies underscore that we still have unanswered questions about the role of serum HDL cholesterol in determining glycemic control among people with T2DM. Although several studies suggest HDL abnormalities may contribute to poor glycemic regulation, their findings are not uniform. Moreover, there is limited local evidence from Indonesia, a country with rapidly increasing T2DM prevalence and unique demographic, dietary, and health-system characteristics. Local data are therefore essential to determine whether HDL is an important predictor of glycemic control in Indonesian patients, particularly in the early years following diagnosis, a critical period for preventing long-term complications.¹⁹

This study aimed to measure the prevalence of poor glycemic control among T2DM cases newly diagnosed in the last 5 years and to identify its influencing factors, as measured by glycosylated hemoglobin.

Methods

This analytical, observational, cross-sectional study was conducted on ambulatory T2DM patients at a public health center in Jakarta from May to June 2023. A total of 114 patients with T2DM were collected by consecutive non-random sampling. The inclusion criteria for prospective subjects were: patients with T2DM if meeting one of the following ADA criteria:²⁰ HbA1c ≥6.5% or fasting blood glucose ≥126 mg/dl (7.0 mmol/l) or 2-hour post prandial blood glucose ≥200 mg/dl (11.1 mmol/l) during the oral glucose tolerance test (OGTT), or random plasma glucose ≥200 mg/dl (11.1 mmol/l); capable of good verbal communication, and agreeing to become study subjects by giving written informed consent. The exclusion criteria were ever receiving or currently

receiving insulin therapy and hypolipidemic drugs, having cardiovascular disease, or abnormal liver or renal function.

The sample size was computed using (1) the formula for an infinite (unknown) population and (2) the formula for a finite (known) population:

$$n_0 = \frac{(Z\alpha^2) \times p \times q}{d} \dots\dots(1)$$

description: n_0 : required optimal sample size, $Z\alpha$: 1.96, p : prevalence of poor glycemic control in diabetes mellitus = 59.2% = 0.592,⁸ q : $(1-p)$ = 0.408, determined degree of confidence or accuracy of measurement = 0.05, resulting in n_0 = 371.

$$n = n_0 / (1 + (n_0/N)) \dots\dots(2)$$

The sample size was calculated using the Dobson formula for a cross-sectional study and adjusted for the finite population. Based on a 59.2% prevalence of poor glycemic control,⁸ 95% confidence, and 5% margin of error, the initial sample size was 371. Given that the total number of persons with T2DM at the study site was 228, the finite population correction yielded a final sample size of 114.

The data collected in this study comprised the characteristics of age, sex, and level of education, followed by the determination of body mass index and drawing of venous blood for the determination of blood lipid concentrations (TC, TG, HDL cholesterol, LDL cholesterol) and of HbA1c for evaluation of the glycemic control of the respondents. Age was categorized into elderly (≥60 years) and non-elderly (<60 years), sex into male and female, and level of education into low (no formal schooling–junior high school) and high (senior high school–tertiary education). Height and weight were determined by means of a portable microtoise and Sage portable scales in accordance with the WHO procedures.²¹

Subjects were asked to remove their footwear, hat, hair accessories, or any high hairdos, take off belts, and empty their pockets to remove cell phones, wallets, or coins. In measuring height, the subject was asked to stand with the feet together, heels against the wall, knees straight, and eyes on the same level as the ears. The measuring arm was gently slid down onto the head, and the subject was asked to breathe in, with the results

recorded to an accuracy of 0.1 cm. To determine body weight, the portable scale was placed on a firm, flat surface. The scale was then switched on until the 0.0 digits appeared. The subject was then asked to step onto the scale, face forward, arms at the sides, and stand still. The weight was recorded to an accuracy of 0.1 cm.

Body mass index (BMI) was calculated by dividing the weight in kg by the square of the height in meters, and was classified into non-obese ($BMI < 25 \text{ kg/m}^2$) and obese ($\geq 25 \text{ kg/m}^2$) in accordance with the WHO Asia-Pacific BMI categories.²²

After an overnight fast of 10 to 12 hours, a total of 10 ml of venous blood was collected in vacutainers with and without EDTA. For HbA1c determination, EDTA-treated blood was directly examined. In contrast, for the determination of blood lipid levels (TC, TG, HDL cholesterol, and LDL cholesterol), venous blood samples without EDTA were centrifuged at 2000 RPM for 10 minutes. The obtained serum was frozen at -70°C before use for laboratory examinations, performed simultaneously on samples from all subjects and assessed by enzymatic colorimetry using the Roche Cobas c111 instrument (Germany). Blood lipids were categorized by means of the criteria of the Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III, or ATP III).²² Total cholesterol was categorized into < 200 and $\geq 240 \text{ mg/dl}$, triglycerides into $< 150 \text{ mg/dl}$ and $\geq 150 \text{ mg/dl}$, HDL cholesterol into ≥ 40 and $< 40 \text{ mg/dl}$, and LDL cholesterol into < 100 and $\geq 100 \text{ mg/dl}$. Glycemic control was based on hemoglobin A1c (HbA1c) concentration and categorized in line with the ADA criteria into good (HbA1c $< 7\%$) and poor (HbA1c $\geq 7\%$).⁵

Data cleaning was performed before data analysis, using consistency, range, and logical checks. We recheck the laboratory value involved by verifying the original laboratory reports, confirming unit consistency, and screening for any data-entry errors. Values represent actual biological variation and not measurement artifacts; we did not apply additional outlier-handling or transformation procedures.

We used the Kolmogorov-Smirnov test to determine the normality of the distribution of all numerical variables. Normally distributed numerical data were presented as mean \pm SD,

whereas non-normally distributed numerical data were presented as median (min–max). Categorical data were presented as the number of respondents (n), percentages (%), odds ratios (OR), and 95% confidence intervals (95% CI). The relationships of socio-demographic characteristics (age, sex, educational level), BMI, and blood lipids with glycemic control were evaluated using simple logistic regression; variables with p-values ≤ 0.25 were then tested in multivariate logistic regression to identify the most influential factors on glycemic control and to control for confounding factors. A two-tailed $p < 0.05$ was considered statistically significant. Statistical analyses were performed using SPSS version 25.0 (IBM Corp., NY, USA). Our study received ethical clearance from the Research Ethics Commission, Faculty of Medicine, Universitas Trisakti, under number 001/KER/FK/1/2022.

Results

The median age of respondents was 56 (35–80) years; the majority were females (72.8%), with the most frequent level of education being senior high school (33.3%). The majority of the subjects (77.2%) had malnutrition, with 1.8% undernutrition, 17.5% overweight, and 39.9% obese. Dyslipidemia was also apparent in the majority of the respondents, with high levels of cholesterol, LDL, and triglycerides. However, the majority of respondents (73.7%) had HDL concentrations $\geq 40 \text{ mg/dl}$. The prevalence of respondents with poor glycemic control was 78 (68.4%). Still, there was no significant difference in age, BMI, or blood lipids between those with poor and good glycemic control (Table 1).

Four variables met the requirements for a multivariable logistic regression ($p < 0.25$): age ($p = 0.091$), level of education ($p = 0.210$), triglyceride concentration ($p = 0.035$), and high-density lipoprotein concentration ($p = 0.007$, Table 2).

The results of multivariate analysis, after adjustment for age, level of education, and triglyceride concentration, showed that the most influential factor of glycemic control in patients with T2DM was HDL cholesterol concentration. Patients with T2DM who had an HDL concentration of $< 40 \text{ mg/dl}$ had 4.43 times higher odds of poor glycemic control compared

Table 1 Subject Characteristics

Variables	All Subjects	Glycemic Control		26 p-value
		Good (n=36)	Poor (n=78)	
Age (years) ^a	56 (35–80)	60 (39–79)	53.50 (35–80)	0.441 ^s
Body mass index (kg/m ²) ^b	26.29±4.57	26.8±5.03	26.04±4.36	0.395 ^s
Blood lipids (mg/dl)				
Total cholesterol ^b	209.47±44.09	201.97±33.17	212.94±48.10	0.161 ^s
Triglycerides ^a	154 (52–1593)	125.5 (61–322)	168.5 (52–1593)	0.060 ^s
HDL cholesterol ^b	45.86±9.65	47 (30–83)	43.5 (24–78)	0.064 ^s
LDL cholesterol ^a	135 (43–324)	135.36±29.5	144.41±43.37	0.259 ^s
Glycemic control, n (%)				
Good	36 (31.6)			
Poor	78 (68.4)			

Note: values presented as median (min–max), bmean±SD. Data analysis: ^aindependent t-test, ^sMann-Whitney test. Classification of categorical data: glycemic control categorized into good (HbA1c <7%) and poor (HbA1c ≥7%)^s

Table 2 Relationship of Several Risk Factors with Glycemic Control in Study Subjects

Variables	Glycemic Control ^a		OR	95% CI	p-value ^b
	Good n=36 (%)	Poor n=78 (%)			
Age (years)					
Non-elderly	17 (25.4)	50 (74.6)	1	0.90–4.45	0.091 ^s
Elderly	19 (40.4)	28 (59.6)	1.99		
Sex					
Female	27 (32.5)	56 (62.5)	1	0.34–2.10	0.721
Male	9 (29.0)	22 (71.0)	0.85		
Level of education					
Low	23 (36.5)	40 (63.5)	1	0.26–1.34	0.210
High	13 (25.5)	38 (74.5)	0.59		
Body mass index (kg/m ²)					
Non-obese	13 (27.1)	35 (72.9)	1	0.64–3.25	0.386
Obese	23 (34.8)	43 (65.2)	1.44		
Blood lipids (mg/dl)					
Cholesterol concentration					
<200	17 (32.7)	35 (67.3)	0.91	0.41–2.01	0.815
≥200	19 (30.6)	43 (69.4)	1		
Triglyceride concentration					
<150	22 (41.5)	31 (58.5)	0.42	0.19–0.94	0.035 ^s
≥150	14 (23.0)	47 (77.0)	1		
HDL concentration					
<40	3 (10.0)	27 (90.0)	5.82	1.63–20.75	0.007 ^s
≥40	33 (39.3)	51 (60.7)	1		
LDL concentration					
<100	3 (30.0)	7 (70.0)	1.08	0.26–4.46	0.910
≥100	33 (31.7)	71 (68.3)	1		

Note: ^aclassification of categorical data: level of education categorized into low (no formal schooling–junior high school) and high (senior high school–tertiary education); age categorized into elderly (≥60 years) and non-elderly (<60 years); BMI categorized into obese (BMI ≥25 mg/kg²) and non-obese (BMI <25 kg/m²); glycemic control categorized into good (HbA1c <7%) and poor (HbA1c ≥7%); OR: odds ratio; CI: confidence interval; ^sstatistical analysis with simple logistic regression test; ^sp-value <0.25 meets requirements for performing analysis with the multivariable logistic regression test

Table 3 Results of Multivariable Logistic Regression Analysis

Variables	aOR	95% CI	P-value ^a
Age (years)			
Non-elderly	1	0.52–3.12	0.594
Elderly	1.28		
Level of education			
Low	1	0.28–1.77	0.458
High	0.71		
Triglyceride concentration (mg/dl)			
<150	0.49	0.20–1.16	0.105
≥150	1		
Glycemic control, n (%)			
<40	4.43	1.19–16.5	0.027*
≥40	1		

Note: aOR: adjusted odds ratio, CI: confidence interval, *statistical analysis with multiple logistic regression test, *statistical significance at p-value <0.05

to those with an HDL concentration of ≥40 mg/dl (Table 3).

Discussion

In our study, poor glycemic control was found in around two-third of the patients or 68.4%, which is higher than in some developing countries, such as Saudi Arabia (49.1%),⁷ and Malaysia (59.2%),⁸ but lower than in others, such as Uganda (84.3%)¹⁰ and Egypt (93%).¹¹ The cause of the different prevalences of poor glycemic control in T2DM may be controlled by various factors, such as socio-demographic characteristics, life style, lack of regular follow up,¹⁹ lack of political will to encourage the communities to improve health issues, and lack of knowledge of T2DM patients about glycemic control.²³ The varying prevalence of glycemic control may also be caused by the different tests used to measure this variable. Moreover, the differing HbA1c cut-off points used to measure blood glucose concentration may also result in the varying prevalences of poor glycemic control. For example, some use HbA1c ≥7% as a cut-off point, while others use HbA1c >7%.²⁴

Based on our study results, most T2DM patients were unable to achieve good glycemic control. This finding should motivate the government and related stakeholders to more actively find solutions for this problem. Knowledge of the predisposing factors of poor glycemic control can be effectively applied to control T2DM and prevent its long-term complications. In this

connection, more efforts should be made to achieve good glycemic control, which requires cooperation between T2DM patients and their health care providers. The latter should not only implement pharmacotherapeutic management but should also actively take promotive and preventive steps by instituting T2DM educational programs, T2DM screening, increasing primary health service capacity and capability, such as strengthening the role of health cadres, standardization of health services, and home visits, where these services agree with the Indonesian MoH policy, namely the transformation of primary health care.²⁵

Our study showed that age was not a risk factor for poor glycemic control in T2DM ($p>0.05$). The survey by Tegegne et al.⁹ showed that older age had 2.12 times the odds of poor glycemic control (aOR=2.12, 95% CI=1.27–2.97). Patrick et al.¹⁰ showed that age of the patients was identified to be an independent risk factor, where middle age and old age had 4.48 and 4.28 times higher odds, respectively, for poor glycemic control than the younger age (aOR=4.48, 95% CI=1.56–14.50, $p=0.009$ and aOR=4.28, 95% CI=1.18–15.58, $p=0.03$, respectively). Different results were shown by Shamshirgaran et al.¹² suggesting that middle age (50–59 years) and old age groups (60 years of age and older) had 0.48 and 0.44 times lower odds, respectively, to having poor glycemic control compared to age under 50 years (aOR=0.49, 95% CI=0.28–0.86 and aOR=0.44, 95% CI=0.24–0.80, respectively). Our study

results differ from those of the studies of Tegegne et al.,⁹ Almalki et al.,⁷ and Patrick et al.,¹⁰ who showed that older age was more vulnerable to poor glycemic control than was younger age, and the study of Shamshirgaran et al.¹² showing that older age had a lower risk of poor glycemic control.

The differences between our study and other studies may have been caused by differences in respondent characteristics, with the median age of 56 (35–80) years showing a lower percentage in the elderly age group (41.3%) than in the non-elderly age group (see Table 1). Lifestyle factors (dietary patterns, physical activity, etc.) may also contribute to individual variation and influence glycemic control. Additionally, the consensus is that aging is often associated with poorer glycemic control in people with diabetes due to physiological changes related to age. In contrast, with advancing age, some persons progressively lose the ability to regulate glucose levels as they did when they were younger, making it difficult for them to maintain stable blood sugar levels.²⁶ However, it has been known that the aging process is not identical between individuals and that other factors may affect glycemic control, such as having diabetes for a longer duration, having comorbidities, and poor adherence to diabetes management,^{9,13} which are significantly associated with higher odds of poor glycemic control.

Our study found that educational level was not a risk factor for poor glycemic control in T2DM. The results of the present study agree with those of Athar et al.,¹⁵ who showed that the level of education is not associated with glycemic control. However, differing results were reported by Bereda et al.,¹⁴ Tegegne et al.,⁹ and Traore et al.,²⁷ indicating that education is negatively associated with glycemic control. This may have resulted from different cutoff points for educational levels, comparing the uneducated with the educated, or comparing the educated with the ignorant. In contrast, in our study, we compared lower education (up to junior high school) with higher education (at least senior high school). The cutoff for glycemic control in our study was A1c level, whereas Bereda et al.¹⁴ used fasting glucose >130 mg/dL.

People with a low level of health literacy have poorer health outcomes, such as a higher risk of complications, hospitalization, higher

treatment costs, and higher mortality risk.^{28,29} The influence of health literacy on glycemic control was shown by the study of Butayeva et al.²⁸ Health literacy depends on several factors, such as individual competence, environmental factors, resources, and community context.³⁰ Therefore the authorities should not rely solely on routine formal education, but should also improve community health literacy. In T2DM, better health literacy is associated with better self-management of diabetes-related skills, better understanding of disease-related knowledge, better treatment adherence, and higher glycemic control.^{28,31}

After controlling for other variables using multivariate analysis, our study showed that low HDL concentrations are risk factors for glycemic control in patients with T2DM (see Table 3). Our results agree with those of Wang et al.¹⁷ and Haghhighatpanah et al.,¹⁶ showing that HDL concentrations were significantly associated with poor glycemic control. Abd-Elraouf et al.¹¹ reported that increased LDL and TC concentrations were significant predictors of increased HbA1c. Artha et al.³² found that the LDL cholesterol-to-HDL cholesterol ratio is the most influential risk factor for poor glycemic control. Different results were reported by Awadalla et al.,¹⁸ who found no significant differences in TG, TC, LDL, and HDL between the glycemic control group and the uncontrolled group. There are noteworthy inconsistencies between studies. The differences in the study population may lead to contradictory results. These findings reveal that glycemic control prevalence can vary even within the same country, depending on the study region. Overall, it can be hypothesized that inadequate glycemic control is associated with dyslipidemia components in T2DM. These inconsistent results may be partly due to the relative stability of HbA1c over time,¹⁷ while blood lipids are dynamically changing.³³ In addition, studies on the relationship between HbA1c and blood lipids at different time points over a period of time may present different results.¹⁷ Because of the association between glycemic control and blood lipids, it is necessary to take both variables into account to prevent T2DM-associated micro- and macrovascular complications. In T2DM, the high prevalence of metabolic dyslipidemia (elevated triglycerides) and low HDL cholesterol levels may be due to increased free fatty acid flux secondary

to insulin resistance.³⁴

The Action for Health in Diabetes (AHEAD) study on 4,199 overweight/obese adults with T2DM but free of CVD shows that participants with metabolic dyslipidemia had a 1.30 higher risk of the composite CVD outcome and a 1.48 higher risk of coronary artery disease events.³⁵ Increasing HDL cholesterol in patients with atherogenic metabolic dyslipidemia may help reduce CVD risk associated with high T2DM prevalence, because each 1-mg/dl increase in HDL cholesterol results in a 2–3% lower CVD risk.³⁶ HDL has antidiabetic effects by inhibiting ER stress-induced beta cell apoptosis³⁷ and by improving insulin sensitivity.³⁸ In T2DM, HDL maintains blood glucose concentrations by also removing excess glucose from the circulation. HDL is also cardioprotective through the mechanism of reverse cholesterol transport, which carries cholesterol and macrophages from atherosclerotic plaques into the liver for excretion from the body^{39,40} and protects against ischemia-induced damage, particularly in the heart, through mediation of tissue glucose for energy production.³⁸

Increasing HDL cholesterol in patients with atherogenic metabolic dyslipidemia may help reduce CVD risk, as each 1-mg/dL increase in HDL is associated with a 2–3% lower risk of CVD.³⁶ HDL also contributes to glucose regulation and insulin sensitivity, providing metabolic benefits relevant to T2DM.^{37,38} Its cardioprotective effects, including its role in reverse cholesterol transport, further support its role in reducing atherosclerotic burden.^{39,40} These established functions offer biological plausibility for the associations observed in our study, and the mechanistic details have been condensed to maintain focus on the study's findings.

Apart from the inconsistencies in blood lipid parameters related to risk factors for poor glycemic control in T2DM patients, the American College of Cardiology/American Heart Association has classified T2DM patients with a higher atherosclerotic CVD risk and has suggested lower intakes of low-density lipoprotein cholesterol.⁴¹ The known controllable cardiovascular risk factors in T2DM include the high prevalence of poor glycemic control, the prominence of high LDL-low HDL dyslipidemia, and the presence of obesity in most respondents. Strategies are needed not

only for glycemic control by administration of anti-glycemic and hypolipidemic medications, but also for improving weight management, including support for lifestyle modification, with adjunctive pharmacotherapy to reduce the risk of cardiovascular disease.

The program of the Indonesian MoH, in the form of the integrated development post (pos binaan terpadu), remains the MoH's strategy as a community-based health initiative and actively provides education and early and curative detection of non-communicable diseases, as exemplified by T2DM blood glucose testing.⁴² Therefore, as a rule, the individuals in question compensate for their poor general education by more focused attendance at clinical education sessions on their illness. Attention is needed when formulating future policies related to health literacy among respondents with a higher level of education. Healthcare professionals can encourage T2DM patients to learn about and acquire knowledge related to diabetes. Interventions such as using social media to access and share reliable sources of diabetes knowledge could be instituted to raise patient health literacy, thereby improving their glycemic control.⁴³

Our study²³ has some limitation. This study did not account for potential confounders, such as dietary intake, physical activity, comorbidities, and medication adherence, which may introduce statistical bias. Serum glucose and lipid metabolism are affected by lifestyle, such as consumption of high-fat and processed foods, which was proven to increase the risk of poor glucose tolerance among overweight or obese adults.⁴⁴ There were also instrument-related methodological limitations, because HbA1c level can be measured by several methods, including cation-exchange chromatography, electrophoresis, immunoassays, and affinity chromatography, each with its own limitations. In addition, the HbA1c content of blood samples depends on erythrocyte lifespan and globin chain properties, not exclusively on blood glucose levels.⁴⁵

Other limitation of our study, as it is well known, the cross-sectional study design does not allow causal inference, so a prospective study is required. The width of the 95% CI for the TG value in our study. It is hoped that future studies will use this study's data as a basis for increasing the number of study samples. We used

consecutive sampling in this study because it was the most practical way to recruit all eligible participants during the study period and to ensure that no cases were intentionally skipped. However, as a non-probability sampling method, consecutive sampling may introduce selection bias, as the sample depends on who presents during the recruitment period. We acknowledge this limitation and have applied consistent eligibility criteria across the entire study period to help reduce potential bias. In this study, oral antihyperglycemic use was recorded, but the small number of users precluded meaningful analysis; therefore, these medications were not included in the main results. Subsequent studies can look into the cause of this phenomenon. Further studies that account for the above-mentioned confounding factors should be conducted to reduce bias. The other factors that should be considered in future studies are low adherence to diabetes management, low family support for diabetes mellitus management, presence of abdominal obesity, and presence of a history of hospitalization, which might be associated with prolonged poor control of T2DM.²⁷

Conclusions

HDL concentrations are potential markers for predicting glycemic control in patients with T2DM. Routine HDL examinations and maintenance of HDL at high concentrations may minimize the risk of complications in T2DM subjects through adjunctive pharmacotherapy, particularly in the population of the present study.

Conflict of Interest

The authors have no conflicts of interest to declare.

Acknowledgment

The researchers would like to thank the subjects of this study for their cooperation.

References

1. GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet*. 2023;402(10397):203–34.
2. Wahidin M, Achadi A, Besral B, Kosen S, Nadjib M, Nurwahyuni A, et al. Projection of diabetes morbidity and mortality till 2045 in Indonesia based on risk factors and NCD prevention and control programs. *Sci Rep*. 2024;14(1):5424.
3. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes Res Clin Pract*. 2022;183:109119.
4. Chen S, Shen Y, Liu YH, Dai Y, Wu ZM, Wang XQ, et al. Impact of glycemic control on the association of endothelial dysfunction and coronary artery disease in patients with type 2 diabetes mellitus. *Cardiovasc Diabetol*. 2021;20(1):64.
5. American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes—2020. *Diabetes Care*. 2020; 43(Suppl 1):S66–76.
6. Chen J, Yin D, Dou K. Intensified glycemic control by HbA1c for patients with coronary heart disease and type 2 diabetes: a review of findings and conclusions. *Cardiovasc Diabetol*. 2023;22(1):146.
7. Almalki ZS, Ahmed NJ, Alahmari AK, Alshehri AM, Alyahya SA, Alqahtani A, et al. Identifying the risk factors and the prevalence of poor glycemic control among diabetic outpatients in a rural region in Saudi Arabia. *J Pharm Res Int*. 2021;33(24A):15–23.
8. Amsah N, Md Isa Z, Kassim Z. Poor glycaemic control and its associated factors among type 2 diabetes mellitus patients in southern part of peninsular Malaysia: a registry-based study. *Open Access Maced J Med Sci*. 2022;10(E):422–7.
9. Tegegne KD, Gebeyehu NA, Yirdaw LT, Yitayew YA, Kassaw MW. Determinants of poor glycemic control among type 2 diabetes in Ethiopia: a systematic review and meta-analysis. *Front Public Health*. 2024;12:1256024.
10. Patrick NB, Yadesa TM, Muhindo R, Lutoti S. Poor glycemic control and the contributing factors among type 2 diabetes mellitus patients attending outpatient diabetes clinic

at Mbarara Regional Referral Hospital, Uganda. *Diabetes Metab Syndr Obes*. 2021; 14:3123–30.

11. Abd-Elraouf MSED. Factors affecting glycemic control in type II diabetic patients. *Egypt J Hosp Med*. 2020;81(2):1457–61.
12. Shamshirgaran SM, Mamaghani A, Aliasgarzadeh A, Aiminisani N, Iranparvar-Alamdari M, Ataie J. Age differences in diabetes-related complications and glycemic control. *BMC Endocr Disord*. 2017;17(1):25.
13. Demoz GT, Gebremariam A, Yifter H, Alebachew M, Nirayyo YL, Gebreslassie G, et al. Predictors of poor glycemic control among patients with type 2 diabetes on follow-up care at a tertiary healthcare setting in Ethiopia. *BMC Res Notes*. 2019;12(1):207.
14. Bereda G, Bereda G. The incidence and predictors of poor glycemic control among adults with type 2 diabetes mellitus in ambulatory clinic of Mettu Karl Referral Hospital, South Western, Ethiopia: a prospective cross sectional study. *Int Arch Endocrinol Clin Res*. 2021;7(1):024.
15. Athar MH, Nisar S, Zubair UB, Mumtaz H. Impact of general education status on glycemic control in patients of diabetes mellitus. *Pak Armed Forces Med J*. 2020; 70(Suppl 1):S26–30.
16. Haghigatpanah M, Nejad ASM, Haghigatpanah M, Thunga G, Mallayasamy S. Factors that correlate with poor glycemic control in type 2 diabetes mellitus patients with complications. *Osong Public Health Res Perspect*. 2018;9(4):167–74.
17. Wang S, Ji X, Zhang Z, Xue F. Relationship between lipid profiles and glycemic control among patients with type 2 diabetes in Qingdao, China. *Int J Environ Res Public Health*. 2020;17(15):5317.
18. Awadalla H, Noor SK, Elmadhoun WM, Bushara SO, Almobarak AO, Sulaiman AA, et al. Comparison of serum lipid profile in type 2 diabetes with and without adequate diabetes control in Sudanese population in north of Sudan. *Diabetes Metab Syndr*. 2018;12(6):961–4.
19. Yahaya JJ, Doya IF, Morgan ED, Ngaiza AI, Bintabara D. Poor glycemic control and associated factors among patients with type 2 diabetes mellitus: a cross-sectional study. *Sci Rep*. 2023;13(1):9673.
20. American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: standards of care in diabetes—2024. *Diabetes Care*. 2023;47(Suppl 1):S20–42.
21. World Health Organization. The WHO STEPwise approach to noncommunicable disease risk factor surveillance [Internet]. Geneva: World Health Organization; 2017 [cited 2025 Aug 23]. Available from: <https://www.who.int/docs/default-source/ncds/ncd-surveillance/steps/steps-manual.pdf>.
22. World Health Organization Western Pasific Region, International Association for the Study of Obesity, International Obesity Task Force. The Asia-Pacific perspective: redefining obesity and its treatment. Sydney: Health Communications Australia Pty Ltd; 2000.
23. Fina Lubaki JP, Omole OB, Francis JM. Glycaemic control among type 2 diabetes patients in sub-Saharan Africa from 2012 to 2022: a systematic review and meta-analysis. *Diabetol Metab Syndr*. 2022;14(1):134.
24. Bin Rakhis SA Sr, AlDuwayhis NM, Aleid N, AlBarraek AN, Aloraini AA. Glycemic control for type 2 diabetes mellitus patients: a systematic review. *Cureus*. 2022;14(6):e26180.
25. Kementerian Kesehatan Republik Indonesia. Transformasi kesehatan Indonesia [Internet]. Jakarta: Kementerian Kesehatan Republik Indonesia; 2025 [cited 2025 2 March]. Available from: <https://kemkes.go.id/id/layanan/transformasi-kesehatan-indonesia>.
26. Chia CW, Egan JM, Ferrucci L. Age-Related Changes in Glucose Metabolism, Hyperglycemia, and Cardiovascular Risk. *Circulation research*. 2018;123(7):886–904.
27. Traore S, Guira O, Zoungrana L, Sagna Y, Bognounou R, Paré B, et al. Factors associated with prolonged poor glycemic control in type 2 diabetes mellitus (T2DM) patients followed in the Department of Internal Medicine at the Yalgado Ouedraogo Teaching Hospital, Ouagadougou (Burkina Faso). *Open J Intern Med*. 2021;11:1–26.
28. Butayeva J, Ratan ZA, Downie S, Hosseinzadeh H. The impact of health literacy interventions on glycemic control and self-management outcomes among type

2 diabetes mellitus: a systematic review. *J Diabetes*. 2023;15(9):724–35.

29. Ong-Artborirak P, Seangpraw K, Boonyathee S, Auttama N, Winaiprasert P. Health literacy, self-efficacy, self-care behaviors, and glycemic control among older adults with type 2 diabetes mellitus: a cross-sectional study in Thai communities. *BMC Geriatr*. 2023;23(1):297.

30. Sørensen K, Levin-Zamir D, Duong TV, Okan O, Brasil VV, Nutbeam D. Building health literacy system capacity: a framework for health literate systems. *Health Promot Int*. 2021;36(Suppl 1):i13–23.

31. Kim S, Song Y, Park J, Utz S. Patients' experiences of diabetes self-management education according to health-literacy levels. *Clin Nurs Res*. 2020;29(5):285–92.

32. Artha IMJR, Bhargah A, Dharmawan NK, Pande UW, Triyana KA, Mahariski PA, et al. High level of individual lipid profile and lipid ratio as a predictive marker of poor glycemic control in type-2 diabetes mellitus. *Vasc Health Risk Manag*. 2019;15:149–57.

33. B O'Donnell V. Lipidomics moves to center stage of biomedicine. *Function (Oxf)*. 2023; 4(1):zqaco71.

34. C Thambiah S, Lai LC. Diabetic dyslipidaemia. *Pract Lab Med*. 2021;26:e00248.

35. Kaze AD, Santhanam P, Musani SK, Ahima R, Echouffo-Tcheugui JB. Metabolic dyslipidemia and cardiovascular outcomes in type 2 diabetes mellitus: findings from the Look AHEAD study. *J Am Heart Assoc*. 2021;10(7):e016947.

36. Ginsberg HN, MacCallum PR. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. *J Cardiometab Syndr*. 2009;4(2):113–9.

37. Lui DTW, Tan KCB. High-density lipoprotein in diabetes: structural and functional relevance. *J Diabetes Investig*. 2024;15(7):805–16.

38. Siebel AL, Heywood SE, Kingwell BA. HDL and glucose metabolism: current evidence and therapeutic potential. *Front Pharmacol*. 2015;6:258.

39. Primer KR, Psaltis PJ, Tan JTM, Bursill CA. The role of high-density lipoproteins in endothelial cell metabolism and diabetes-impaired angiogenesis. *Int J Mol Sci*. 2020; 21(10):3633.

40. Kalumpiu J, Herwana E, Yenny Y, Kurniasari K. Blood pressure, total cholesterol, and triglycerides associated with cardiovascular risk score in low 25-hydroxy vitamin d level among online motorcycle drivers, Jakarta, Indonesia. *GMHC*. 2024;12(1):46–53.

41. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2019;73(24):e285–350.

42. Kementerian Kesehatan Republik Indonesia. Direktorat Jendral Pencegahan dan Pengendalian Penyakit. Buku pintar kader posbindu. Jakarta: Kementerian Kesehatan Republik Indonesia; 2019.

43. Elnaggar A, Ta Park V, Lee SJ, Bender M, Siegmund LA, Park LG. Patients' use of social media for diabetes self-care: systematic review. *J Med Internet Res*. 2020;22(4):e14209.

44. Liman PB, Anastasya KS, Salma NM, Yenny Y, Faradilla MA. Research trends in advanced glycation end products and obesity: bibliometric analysis. *Nutrients*. 2022;14(24):5255.

45. Chen Z, Shao L, Jiang M, Ba X, Ma B, Zhou T. Interpretation of HbA1c lies at the intersection of analytical methodology, clinical biochemistry and hematology (review). *Exp Ther Med*. 2022;24(6):707.

Serum High-Density Lipoprotein-Cholesterol Concentration as Determinant of Poor Glycemic Control in Type 2 Diabetes Mellitus Patients at a Public Health Center in Jakarta, Indonesia

ORIGINALITY REPORT

18

SIMILARITY INDEX

PRIMARY SOURCES

1	www.univmed.org	68 words — 1%
2	doczz.net	65 words — 1%
3	Armelia Sari Widyarman, Muhammad Ihsan Rizal, Moehammad Orliando Roeslan, Carolina Damayanti	38 words — 1%
4	Emmanuel Opara. "NUTRITION and DIABETES – Pathophysiology and Management", CRC Press, 2005	33 words — 1%
5	www.academicmed.org	31 words — 1%
6	www.banglajol.info	28 words — 1%
7	Jingfeng Chen, Lina Wen, Guifen Fu, Chaoqun Bai,	25 words — < 1%

Xiaoxue Lei, Yanping Zhang. "The relationship

between health literacy and blood sugar control in rural areas among diabetes patients", *Frontiers in Endocrinology*, 2024

Crossref

8 ispub.com
Internet 25 words – < 1%

9 keep.lib.asu.edu
Internet 25 words – < 1%

10 pdfs.semanticscholar.org
Internet 24 words – < 1%

11 www.hkcfp.org.hk
Internet 22 words – < 1%

12 repository.maseno.ac.ke
Internet 20 words – < 1%

13 **Medha N. Munshi, Lewis A. Lipsitz. "Geriatric Diabetes", CRC Press, 2007**
Publications 18 words – < 1%

14 **Chontira Riangkam, Supaporn Sanguanthammarong, Raweewan** 17 words – < 1%

Lertwattanarak. "Determinants of Glycemic Control in Thai Adults with Insulin–Treated Type 2 Diabetes Mellitus: A Cross– Sectional Study", *Patient Preference and Adherence*, 2025

Crossref

15 **Lingkan Barua, Mithila Faruque, Shagoofa Rakhshanda, Palash Chandra Banik, Riffat Ara** 17 words – < 1%

Shawon, Saidur Rahman Mashreky. "Baseline prevalence of high blood pressure and its predictors in a rural adult population of Bangladesh: Outcome from the application of WHO PEN

interventions", The Journal of Clinical Hypertension, 2021

[Crossref](#)

16 pure.rug.nl
Internet 17 words – < 1%

17 www.econ.cuhk.edu.hk
Internet 17 words – < 1%

18 uniassignment.com
Internet 16 words – < 1%

19 thws.bibkatalog.de
Internet 15 words – < 1%

20 www.biomedcentral.com
Internet 14 words – < 1%

21 synapse.koreamed.org
Internet 13 words – < 1%

22 Arnaud D. Kaze, Prasanna Santhanam, Solomon K. Musani, Rexford Ahima, Justin B. Echouffo- 12 words – < 1%

Tcheugui. "Metabolic Dyslipidemia and Cardiovascular Outcomes in Type 2 Diabetes Mellitus: Findings From the Look AHEAD Study", Journal of the American Heart Association, 2021
Crossref

23 Ji-Hye Lee, So-Young Park, Min-Seok Jo, Jae-Woo Park, Jinsung Kim, Seok-Jae Ko. "The Effect of 11 words – < 1%

Dioscoreae Rhizoma on Gastrointestinal Function: A Systematic Review", Nutrients, 2025
Crossref

24 25 K Moriya. "Serum lipid profile of patients with genotype 1b hepatitis C viral infection in Japan", Hepatology Research,

200

3 11 words – < 1%

Crossr
ef

bac

koff

ice.

bibl

io.u

gen

t.be

Interne
t

26 d.docksci.com
Internet 11 words – < 1%

27 e-journal.unair.ac.id
Internet 11 words – < 1%

28 www.coursehero.com
Internet 11 words – < 1%

29 www.johnshopkinshealthalerts.com
Internet 11 words – < 1%

30 www.jstage.jst.go.jp
Internet 11 words – < 1%

31 Farooq Wani, Saeed AlMutyif, Altaf Bandy,
Ashokkumar Thirunavukkarasu, Ekremah Alzarea, 10 words – < 1%
Muath Alsurur, Basil Alomair. "Diabetic Complication Profiles
and Associated Risk Factors: A Comprehensive Analysis from
Two Public Hospitals in the Najran Region, Southern Saudi
Arabia", Medicina, 2025
Crossref

32 Rezan Koçak Ulucaköy, Ayza Kılıç, Sevilay Batıbay, 10 words – < 1%
İdil Melis Çobanoğlu et al. "Can serum
granulocyte–macrophage colony–stimulating factor and CCL17
levels be a marker of disease activation in spondyloarthritis?",
Archives of Rheumatology, 2024
Crossref

33 goums.ac.ir
Internet 10 words – < 1%

34 mafiadoc.com
Internet 10 words – < 1%

35 Henry N. Ginsberg. "The Obesity, Metabolic
Syndrome, and Type 2 Diabetes Mellitus 9 words – < 1%

Pandemic: Part I. Increased Cardiovascular Disease Risk and the Importance of Atherogenic Dyslipidemia in Persons With the Metabolic Syndrome and Type 2 Diabetes Mellitus", Journal of the CardioMetabolic Syndrome, 03/2009

Crossref

36	cdr.lib.unc.edu	9 words – < 1%
37	e-pan.org	9 words – < 1%
38	healthjade.com	9 words – < 1%
39	library.unisel.edu.my	9 words – < 1%
40	mdpi-res.com	9 words – < 1%
41	onlinelibrary.wiley.com	9 words – < 1%
42	rcastoragev2.blob.core.windows.net	9 words – < 1%
43	viendinhduong.vn	9 words – < 1%
44	www.erinpharm.org	9 words – < 1%
45	Paul Muntner. "Association of High-Density Lipoprotein Cholesterol With Coronary Heart	8 words – < 1%

Disease Risk Across Categories of Low-Density Lipoprotein Cholesterol: The Atherosclerosis Risk in Communities Study :", The

46 Ramona Al-Zoairy. "Lipid profile changes after pronounced weight loss induced by bariatric surgery", *Clinical Lipidology*, 04/2012
Crossref 8 words – < 1%

47 Sher Muhammad Sethi, Iffat Khanum, Umair Javed, Sania Sabir. "Impact of Infection on Glycemic Control in Diabetic Patients; a Hospital-based Cohort Study in Pakistan", *Afro-Egyptian Journal of Infectious and Endemic Diseases*, 2022
Crossref 8 words – < 1%

48 Tamara Štemberger-Kolnik, Andreja Ljubič, Bojana Filej, Mojca Poredoš, Boris Miha Kaučič. 8 words – < 1%

"Differences in Health Literacy of Older Adults According to Sociodemographic Characteristics", *Open Access Macedonian Journal of Medical Sciences*, 2022
Crossref

49 Tevfik KOÇAK, Eda KÖKSAL, Mujde AKTÜRK. "Association between serum 1,5-anhydroglucitol, 8 words – < 1%"
dietary energy density and lifestyle factors in women with newly diagnosed type 2 diabetes", *Springer Science and Business Media LLC*, 2025
Crossref Posted Content

50 cardiab.biomedcentral.com
53 cris.unibo.it
51 digital.car.chula.ac.th
52 Internet Internet Internet

dms 8 words – < 1%

jour

nal.

bio 8 words – < 1%

me

dce

ntra 8 words – < 1%

l.co

m

Interne 8 words – < 1%

t

lipi

dwo

rld.

bio

me

dce

ntra

l.co

m

Internet

54 mail.innovareacademics.in 8 words – < 1%

55 Internet 8 words – < 1%

56 moam.info 8 words – < 1%

57 Internet 8 words – < 1%

58 ugspace.ug.edu.gh 8 words – < 1%

59 www.science.gov 8 words – < 1%

EXCLUDE QUOTES

ON EXCLUDE BIBLIOGRAPHY ON

